BOSTON SCIENTIFIC CORP 8-K

What Happened
Boston Scientific Corporation announced on May 18, 2026 that it entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, N.A. for $2.0 billion as part of its previously authorized $5.0 billion share repurchase program. The company paid the repurchase price and initially received common stock equal to 80% of that amount based on the May 15, 2026 closing price, which represents approximately 30.4 million shares using the $52.68 closing price.

Key Details

• ASR amount: $2.0 billion; counterparty: JPMorgan Chase Bank, N.A.
• Initial shares delivered: ~30.4 million shares (based on May 15, 2026 close of $52.68), representing 80% of the repurchase price at initiation.
• Final shares to be repurchased will be determined by the volume-weighted average price (VWAP) during the ASR term, adjusted for a discount per the ASR agreement.
• Expected final settlement: by June 30, 2026. After the ASR, $3.0 billion remains available under the $5.0 billion repurchase authorization.

Why It Matters
This ASR is a use of capital to buy back shares, which can reduce outstanding shares and potentially support earnings per share over time. Investors should note the initial delivery is based on a fixed reference date price, but the final number of shares repurchased will adjust based on actual VWAP during the ASR term, so the ultimate share count and exact impact on float and per-share metrics will be finalized at settlement. The filing also includes customary forward-looking cautionary language about risks and uncertainties.